ClinicalTrials.gg
RecruitingNCT07081373Updated Jul 23, 2025

Study on Repeat Liposomal Bupivacaine for Post-Surgery Pain in Anal Fistula Patients.

An interventional study of A single dose of liposomal bupivacaine is administered at the conclusion of surgery without adjunctive analgesics, followed by a supplemental dose 72 hours postoperatively. in Anal Fistula, sponsored by Sixth Affiliated Hospital, Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-07-23.

Sponsored by Sixth Affiliated Hospital, Sun Yat-sen University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
408
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Rectal Fistula with a site in China — 6 open to participants now, 6 under way, none of them phase 3. Rectal Fistula · China.

Planned enrollment
Largest of 15
408 · median 92
Started
2025
with 2 others
No phase
11 of 17
3 open now
Registered
12th of 17
by date
Lead sponsor
3 of 17
Sixth Affiliated Hospital, Sun Yat-sen University

Among the 17 studies in Rectal Fistula with a site in China, this one has the largest planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2025, is one of 11 with no phase, and was the 12th registered.

Rectal Fistula

170 studies on the registry are indexed under Rectal Fistula; 45 are open to participants now.

Browse Rectal Fistula studies →

Open to participants now

6 of the 17 studies in Rectal Fistula with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 26 Rectal Fistula studies recruiting now, 18 (69%) set no upper age limit and 7 (27%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Rectal Fistula with a site in China, or all of them as a file.
02

Study summary

Anal Fistula refers to an abnormal infectious fistula tract between the anorectum and the perianal skin. The prevalence of anal fistula is approximately 8.6 cases per 100,000 individuals. It can occur at any age but is relatively more common in individuals aged 20-40 years, with a higher incidence in males than females.

Postoperative wound management is a critical component of the overall treatment for anal fistula patients. Regular postoperative wound care, such as dressing changes, can reduce recurrence rates, alleviate pain, and shorten hospitalization time. However, postoperative pain remains a major challenge in wound management following anal fistula surgery. This is largely attributed to inadequate current postoperative analgesic protocols.

With ongoing advancements in local anesthetics, liposomal bupivacaine has been applied for postoperative analgesia. It offers higher bioavailability and a prolonged half-life, providing up to 72 hours of sustained analgesic effect. Given the limitations of existing analgesic strategies for post-anal fistula surgery, developing more effective pain management approaches to reduce postoperative pain holds significant clinical importance.

Therefore, the investigators propose that a repeat-dosing strategy based on liposomal bupivacaine may provide superior postoperative pain control for anal fistula patients. To investigate this, the investigators designed a prospective, multicenter, randomized, open-label, controlled clinical trial. This study aims to evaluate the efficacy and safety of repeat-dose liposomal bupivacaine for postoperative analgesia following anal fistula surgery, thereby generating high-level evidence to support its clinical application in this context.

03

Conditions studied

  • Anal Fistula

Keywords

  • Anal fistula
  • Bupivacaine liposome
  • Postoperative pain
  • Repeat dosing
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with anal fistula and scheduled to undergo anal fistula surgery;
  • Aged between 18 and 60 years;
  • ASA () physical status class I-II;
  • Patient provides written after understanding the study protocol.

Exclusion criteria

Exclusion Criteria:

  • Anal fistula caused by specific etiologies (e.g., tuberculosis);
  • Concurrent acute perianal skin infection;
  • Poorly controlled diabetes ( >9%);
  • Chronic use of ;
  • History of radiotherapy or chemotherapy within the past 2 weeks;
  • Pregnancy or lactation;
  • to local anesthetics or any component of the drug;
  • History of substance abuse, illicit drug use, or alcohol abuse;
  • Use or planned use of non-opioid/opioid analgesics within 12 hours before/during surgery;
  • Concurrent treatment with anticonvulsants, MAO inhibitors, antidepressants, neuromuscular blockers, or anticholinergics within 2 weeks prior to surgery;
  • Severe hepatic/renal impairment, cardiopulmonary dysfunction, coagulation disorders, or comorbidities contraindicating surgery;
  • History of severe psychiatric disorders or cognitive impairment;
  • Sensory disorders (e.g., hyperalgesia) or preexisting pain interfering with postoperative pain assessment;
  • to amide-type local anesthetics, opioids, or propofol;
  • Participation in investigational drug trials within 90 days prior to enrollment;
  • Other clinical/laboratory conditions deemed by investigators to preclude trial participation.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
408 participants (estimated)

Study arms

  • Experimental
    Liposomal Bupivacaine Repeat Dosing Group

    A single dose of liposomal bupivacaine is administered at the conclusion of surgery without adjunctive analgesics, followed by a supplemental dose 72 hours postoperatively.

    Drug: A single dose of liposomal bupivacaine is administered at the conclusion of surgery without adjunctive analgesics, followed by a supplemental dose 72 hours postoperatively.

  • No intervention
    Liposomal Bupivacaine Single-Injection Group

    A single dose of liposomal bupivacaine is administered at the conclusion of surgery without adjunctive analgesics.

Interventions

  • DrugA single dose of liposomal bupivacaine is administered at the conclusion of surgery without adjunctive analgesics, followed by a supplemental dose 72 hours postoperatively.

    At surgical closure, a single dose of undiluted liposomal bupivacaine (266 mg/20 mL) is administered without concurrent analgesics. The total 20 mL volume is divided into six equal aliquots (≈3.3 mL each) and infiltrated circumferentially around the incision using a 25-gauge or larger-bore needle. Injections target tissue layers above and below the fascia and within the subcutaneous plane, with frequent aspiration during administration to mitigate intravascular injection risk. Seventy-two hours postoperatively, a repeat dose of undiluted liposomal bupivacaine (266 mg/20 mL) is administered. Prior to infiltration, topical lidocaine cream is applied to the per-incisional skin for ≥20 minutes. The full 20 mL volume is then injected uniformly around the incision via circumferential needle advancement into pericicatricial tissues.

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC) of the Numerical Rating Scale (NRS) for pain within 7 Days postoperatively (NRS-AUC0-168h)

    Numerical rating scale, a numerical rating scale where participants select a number from 0 to 10 based on their subjective pain experience. On this scale: 0 represents no pain; 10 represents the most severe pain imaginable.

    Time frame: 7 days postoperatively

Secondary outcomes

  1. Numerical Rating Scale (NRS) for pain during wound dressing changes within 7 days postoperatively

    Numerical rating scale, a numerical rating scale where participants select a number from 0 to 10 based on their subjective pain experience. On this scale: 0 represents no pain; 10 represents the most severe pain imaginable.

    Time frame: 7 days postoperatively

  2. Area Under the Curve (AUC) of the Numerical Rating Scale (NRS) for pain from 96 to 168 hours postoperatively (NRS-AUC96h-168h)

    Time frame: 96 to 168 hours postoperatively

  3. Number of breakthrough pain episodes and corresponding Numerical Rating Scale (NRS) scores during episodes

    Numerical rating scale, a numerical rating scale where participants select a number from 0 to 10 based on their subjective pain experience. On this scale: 0 represents no pain; 10 represents the most severe pain imaginable.

    Time frame: 7 days postoperatively

  4. Postoperative 7-day cumulative consumption of all analgesic drugs (calculated as morphine equivalents)

    Time frame: 7 days postoperatively

  5. Postoperative 7-day cumulative consumption of rescue analgesic drugs (calculated as morphine equivalents)

    Time frame: 7 days postoperatively

  6. Safety (including incidence of postoperative adverse events and serious adverse events): Adverse events and serious adverse events occurring within 14 days after medication were assessed

    Time frame: 14 days after medication were assessed

  7. Postoperative heart rate monitoring: Heart rate at 24h, 48h, 72h, 96h, 120h, 144h, and 168h postoperatively.

    Time frame: At 24, 48, 72, 96, 120, 144, and 168 hours postoperatively.

  8. Postoperative blood pressure monitoring: systolic blood pressure, and diastolic blood pressure at 24h, 48h, 72h, 96h, 120h, 144h, and 168h postoperatively.

    Time frame: At 24, 48, 72, 96, 120, 144, and 168 hours postoperatively.

  9. SF-12 scores at preoperative, 1 week, 1 month, and 2 months postoperatively.

    The 12-Item Short Form Health Survey (SF-12) is a widely used concise instrument developed by the Medical Outcomes Study (MOS) to assess an individual's health-related quality of life (HRQoL), derived as an abbreviated version of the SF-36 scale. Overall scores range from 0 to 100, with higher scores representing better health status.

    Time frame: 1 week, 1 month, and 2 months postoperatively.

  10. Preoperative, 14-day postoperative, and 1-month postoperative Wexner Incontinence Scores

    The Wexner Incontinence score, also termed the Cleveland Clinic Fecal Incontinence Severity Scoring System (CCIS) is a fecal incontinence score from 0-20; where 0 is perfect continence and 20 is complete incontinence.

    Time frame: Prior to surgery; 14 days after surgery; 1 month postoperatively.

  11. Analgesia satisfaction: Postoperative analgesic satisfaction was assessed using a 5-point categorical scale at 24h, 96h, and 168h postoperatively.

    The Postoperative Analgesia Satisfaction Scale is an investigator-developed instrument where participants select a number from 0 to 4 based on their subjective experience, with higher scores representing greater satisfaction.

    Time frame: At 24, 96, and 168 hours postoperatively.

  12. Wound healing rate within 8 weeks postoperatively.

    Wound Healing Rate: The wound area on postoperative day 1 is defined as the initial wound area. Measure the maximum length and perpendicular width of the wound to calculate the wound area. Formula: Wound Healing Rate = \[(Initial Area - Current Area) / Initial Area\] × 100%.

    Time frame: 8 weeks postoperatively

  13. Wound healing time within 8 weeks postoperatively.

    Wound Healing Time: The duration from initial dressing change until complete wound epithelialization is achieved.

    Time frame: 8 weeks postoperatively

  14. Wound Edema Score within 8 weeks postoperatively.

    Wound Edema Scoring Criteria: 3 points: Severe edema with gross elevation beyond wound margins, requiring surgical intervention; 2 points: Significant edema extending beyond wound margins, managed with dressing changes; 1 point: Mild localized edema; 0 points: No detectable edema.

    Time frame: 8 weeks postoperatively

  15. Wound granulation tissue color score within 8 weeks postoperatively.

    Granulation Tissue Color Scoring: 1. point: Bright red; 2. points: Pale red; 3. points: Purple.

    Time frame: 8 weeks postoperatively.

  16. Whether the wound is infected within 8 weeks postoperatively.

    Time frame: 8 weeks postoperatively.

  17. Whether the wound is bleeding within 8 weeks postoperatively.

    Whether bleeding is present (none, oozing, active)

    Time frame: 8 weeks postoperatively.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for Jun 2026, 11 months later.

Of 54 non-industry interventional studies with no phase under Rectal Fistula, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 36. This study's planned 11 months is below that.

Counting every sponsor, half of 58 studies reached it within 27 months; a quarter within 11 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2025
First posted
Jul 23, 2025
StartEst.
Jul 16, 2025
Primary completionEst.
Jun 30, 2026
CompletionEst.
Jun 30, 2027
Last update
Jul 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07081373
Collaborators
First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Maoming People's Hospital, Dongguan Hospital of Traditional Chinese Medicine, Xingyi People's Hospital, Nanjing Hospital of C. M., People's Hospital of Xinjiang Uygur Autonomous Region
Responsible party
Sponsor
First posted
Jul 23, 2025
Start date
Jul 16, 2025 (estimated)
Primary completion
Jun 30, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Jul 23, 2025

Study contacts

Hongcheng Lin, MD
Contact
lhcheng@mail.sysu.edu.cn
+86 15915815776

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion